Cagrilintide

Name: Cagrilintide
Brand: Peak Research Peptides
SKU: PRP-CAGRILINTI
Price: 115.00 USD
Availability: OutOfStock

Synthetic amylin-receptor peptide supplied for in-vitro receptor research.

Receptors & targets

AMY receptorsCalcitonin receptor

Sequence / structure

Synthetic long-acting acylated amylin-analog peptide.

Handling

Storage: Store lyophilized at −20 °C. Protect from light.

Verified before release

Every lot of Cagrilintide is analysed against the specification below before any vial is released.

≥0.00%purity by HPLC · specification ≥ 95%

Parameter	Result	Method	Specification
Appearance	White lyophilised powder	Visual	White lyophilised powder
Purity	≥ 99.00%	HPLC	≥ 95%
Identity	Confirmed	HPLC / MS	Meets specification
Heavy metals	Not detected	ICP-MS	Pass
Sterility	No growth	PCR	Pass
Endotoxin	Within limit	USP <85>	Report

Analysis is carried out on every lot before release. If you are supplying material onward, run your own confirmatory testing on arrival — our work supports yours, it does not replace it.

Specification

Presentation: 5 mg / vial
Molecular formula: C194H312N54O59S2
Molecular weight: 4409.0 g/mol
CAS: 1415456-99-3
Grade: Research use only (RUO)

$115.00

Dosage

5 mg / vial — sold out

For laboratory and research purposes only. Not for human or animal consumption.

Published literature

Peer-reviewed research on Cagrilintide, indexed in PubMed. Listed so you can read the primary sources directly.

Lancet Diabetes Endocrinol
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Buse JB, Bajaj HS, Dalskov SM et al.
2026PMID 42251859DOI
N Engl J Med
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies MJ, Bajaj HS, Broholm C et al.
2025PMID 40544432DOI
N Engl J Med
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK et al.
2025PMID 40544433DOI
EBioMedicine
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
Carvas AO, Leuthardt A, Kulka P et al.
2025PMID 40609154DOI
N Engl J Med
Cagrilintide-Semaglutide in Adults with Overweight or Obesity
Chi H, Yang H, Deng Y
2025PMID 41259767DOI
Cardiol Rev
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio AM, Mullally JA, Frishman WH
2024PMID 36883831DOI

These papers are the published research on this molecule. They are not a claim about this product, and nothing here describes an intended use. All material is supplied for laboratory research only.